Clinical feasibility of a label-free SERS assay for therapeutic drug monitoring of methotrexate

被引：3

作者：

Dumont, Elodie ^{[1
,2
]}

Soufi, Gohar ^{[1
,2
]}

Goksel, Yaman ^{[1
,2
]}

Slipets, Roman ^{[1
,2
]}

Raja, Raheel Altaf ^{[3
]}

Schmiegelow, Kjeld ^{[3
]}

Zor, Kinga ^{[1
,2
]}

Boisen, Anja ^{[1
,2
]}

机构：

[1] Tech Univ Denmark, Ctr Intelligent Drug Delivery & Sensing Using Micr, Dept Hlth Technol, DK-2800 Lyngby, Denmark

[2] BioInnovat Inst Fdn, DK-2200 Copenhagen N, Denmark

[3] Rigshosp Univ Hosp, Dept Paediat & Adolescent Med, DK-2100 Copenhagen, Denmark

来源：

SENSING AND BIO-SENSING RESEARCH | 2024年 / 44卷

基金：

新加坡国家研究基金会;

关键词：

SERS; Methotrexate (MTX); Silver nanopillars (AgNPs); Method comparison; Chemometrics; Therapeutic drug monitoring (TDM);

D O I：

10.1016/j.sbsr.2024.100649

中图分类号：

O65 [分析化学];

学科分类号：

070302 ; 081704 ;

摘要：

We present a therapeutic drug monitoring (TDM) feasibility study using a label-free surface-enhanced Raman spectroscopy (SERS)-based assay for quantifying methotrexate (MTX) from samples collected from children with acute lymphoblastic leukemia undergoing high-dose MTX therapy. We show that, when combined with an appropriate sample preparation (solid phase extraction) and multivariate data analysis (partial least squares regression), the SERS assay demonstrated a good correlation with a reference chromatographic method (r = 0.889, p < 0.005). We also found that the SERS-based approach underestimated MTX concentration, with a 10% bias calculated, but both methods showed similar variability (RSD of 8.4% for HPLC and 11.6% for SERS). The presented results are strong evidence that SERS can be used for TDM of MTX, and this work brings us one step closer to implementing a SERS-based assay in clinics.

引用

页数：7

共 38 条

[1]

Agogo-Mawuli Percy S, 2022, Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology, P233

[2]

Amponsah S.K., 2022, Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology, P369

[3]

[Anonymous], Cobas® 8000 modular analyzer series

[4]

ARKTM Methotrexate Assay (Trexall®), about us

[5]

Basu B., 2022, Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology, P95

[6] Clinical Validation of SERS Metasurface SARS-CoV-2 Biosensor [J].

Bilgin, Buse ;

Torun, Hulya ;

Ilgu, Muslum ;

Yanik, Cenk ;

Batur, Numan ;

Celik, Suleyman ;

Ozturk, Meric ;

Dogan, Ozlem ;

Ergonul, Onder ;

Solaroglu, Ihsan ;

Can, Fusun ;

Onbasli, Mehmet Cengiz .

BIOMEDICAL VIBRATIONAL SPECTROSCOPY 2022: ADVANCES IN RESEARCH AND INDUSTRY, 2022, 11957

[7]

Booth B.P., 2016, New Drug Dev. Regul. Paradig. Clin. Pharmacol. Biopharm, P138, DOI [DOI 10.1201/9780203026427-15, 10.1201/9780203026427-15]

[8] Comparison of various international guidelines for analytical method validation [J].

Chandran, S. ;

Singh, R. S. P. .

PHARMAZIE, 2007, 62 (01) :4-14

[9] Clinical validation of surface-enhanced Raman scattering-based immunoassays in the early diagnosis of rheumatoid arthritis [J].

Chon, Hyangah ;

Wang, Rui ;

Lee, Sangyeop ;

Bang, So-Young ;

Lee, Hye-Soon ;

Bae, Sang-Cheol ;

Hong, Sung Hyun ;

Yoon, Young Ho ;

Lim, Dong Woo ;

deMello, Andrew J. ;

Choo, Jaebum .

ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2015, 407 (27) :8353-8362

[10] Comparison of four immunoassays to an HPLC method for the therapeutic drug monitoring of methotrexate: Influence of the hydroxylated metabolite levels and impact on clinical threshold [J].

Descoeur, Juliette ;

Dupuy, Anne-Marie ;

Bargnoux, Anne-Sophie ;

Cristol, Jean-Paul ;

Mathieu, Olivier .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) :55-63

← 1 2 3 4 →